

Amendments to the Specification:

Please amend the specification as follows:

Please replace the Title on page 1 with the following:

--Compositions of Angiopoietin, fragments, mutants and analogs thereof and uses of the same--

Please replace the paragraph on page 27, line 14, of the specification with the following:

--Two Ang-I mutants have been established in which either the linker peptide region of Ang-I (₂₅₈VHNLVSL₂₆₅CTKEGVLLKGGKREEEKPF₂₈₃) (SEQ ID NO. 37) was deleted (Ang-1_{minuslinker}) or the Cys265 residue in the region was mutated to Ser (Ang-1_{cys265ser}).--

Please replace the paragraph on page 28, line 19, of the specification with the following:

--A peptide, L₂₆₅CTKEGVLLKGGKREEEKPF₂₈₃ (SEQ ID NO. 38), derived from the linker peptide region was found to inhibit the incorporation of Ang-1 proteins to the ECM in cell culture condition. This result suggests that the linker peptide or its derivatives (peptides and small molecules) can potentially be used to modulate the ECM binding of Ang-1, therefore the bioactivity and availability of Ang-1.--

Please replace the paragraph on page 35, line 20, of the specification with the following:

--It has been shown recently that the linker peptide region between the coiled-coil and the fibrinogen-homology domain (FHD) of Ang-1 likely mediates that interaction between Ang-1 and the ECM (32). The linker peptide region contains 26 amino acids (₂₅₈VHNLVSL₂₆₅CTKEGVLLKGGKREEEKTF₂₈₃) (SEQ ID NO. 39), and is highly conserved among different species. There is 96% identity at the amino acid level between human and mouse in this region. To confirm that the linker peptide region mediates the ECM binding of Ang-1 and determine the role of the cysteine265 residue, which is conserved among different